Theralase(r) release's 3q2024 financial statements

Toronto, on / accesswire / november 27, 2024 / theralase® technologies inc. (" theralase® " or the " company ") (tsxv:tlt)(otcqb:tltff), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses has released the company's unaudited condensed consolidated interim financial statements for the nine-month period ended september 30, 2024. (" financial statements ").
CAN Ratings Summary
CAN Quant Ranking